



PATENT

1PW

Case Docket No. ACADIA.031A

Date: July 15, 2004

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Weiner, et al.  
Appl. No. : 10/761,787  
Filed : January 21, 2004  
For : USE OF N-DESMETHYLCLOZAPINE TO TREAT HUMAN NEUROPSYCHIATRIC DISEASE  
Examiner : Unknown  
Group Art Unit : 1614

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Mail Stop Amendment, P.O. Box 1450, Alexandria, VA 22313-1450, on

July 15, 2004

(Date)

Sam K. Tahmassebi, Reg. No. 45,151

## TRANSMITTAL LETTER


Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) A Supplemental Information Disclosure Statement.
- (X) A PTO Form 1449 with seven (7) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Sam K. Tahmassebi  
Registration No. 45,151  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550



## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant	:	Weiner, et al.
App. No.	:	10/761,787
Filed	:	January 21, 2004
For	:	USE OF N-DESMETHYLCLOZAPINE TO TREAT HUMAN NEUROPSYCHIATRIC DISEASE
Examiner	:	Unknown
Group Art Unit	:	1614

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing seven references that are also enclosed.

This Information Disclosure Statement is being filed before the mailing date of a final action under 37 C.F.R. § 1.113 and before the mailing date of a Notice of Allowance under § 1.311. A certification under 37 C.F.R. § 1.97(e) is set forth below. Thus, no fee is required as set forth in 37 C.F.R. § 1.97(c).

EXPLANATION UNDER 37 C.F.R. § 1.98(a)(3)(i)

The relevance of French Patent FR 51 F is that it depicts N-desmethylozapine in Table 2, Example 9 and contains a statement on page 5, left hand column, that the International Search Authority stated disclosed a tablet preparation that was "a neuroleptic useful in the treatment of psychosis."

**Appl. No.** : 10/761,787  
**Filed** : January 21, 2004

**Docket No.** ACADIA.031A  
**Customer No.** 20,995

CERTIFICATION UNDER 37 C.F.R. § 1.97(e)(1)

I hereby certify that each item of information contained in this Statement was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than 30 days prior to the filing of this Information Disclosure Statement.


Respectfully submitted,  
KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: July 15, 2004

By: Sam K. Tahmassebi  
Sam K. Tahmassebi  
Registration No. 45,151  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550

S:\DOCS\REM\REM-1487.DOC:sad  
071504

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ACADIA.031A	APPLICATION NO. 10/761,787
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Weiner, et al.	
		FILING DATE January 21, 2004	GROUP 1614



FOREIGN PATENT DOCUMENTS									
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
							YES	NO	
	1	WO 02/060870	08/08/02	WIPO					
	2	FR 51	04/06/64	France					

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
	3	Özdemir, V., et al., "CYP1A2 Activity as Measured by a Caffeine Test Predicts Clozapine and Active Metabolite Norclozapine Steady-State Concentration in Patients With Schizophrenia," <i>Journal of Clinical Psychopharmacology</i> , 21:4(398-407), August 2001.						
	4	Spina, E., et al., "Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia," <i>International Clinical Psychopharmacology</i> , 13:141-145, 1998.						
	5	Sur, C., et al., "N-desmethylozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity," <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 100:23(13674-13679) Nov. 11, 2003.						
	6	Weigmann, H., et al., "Does the pharmacologically active N-demethylated metabolite of clozapine pass the blood-brain barrier?" <i>Pharmacopsychiatry</i> , and "20 <sup>th</sup> Symposium of AGNP, Nuremberg, Germany," 30:5(233), September 1997.						
	7	Young, C., et al., "Effects of Desmethylozapine on Fas Protein Expression in the Forebrain: In Vivo Biological Activity of the Clozapine Metabolite," <i>Neuropsychopharmacology</i> , 19:1(99-103) 1998.						

S:\DOCS\REM\REM-1486.DOC:sad  
071504

EXAMINER	DATE CONSIDERED
<b>*EXAMINER:</b> INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	